Zhuhai Rundu Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhuhai Rundu Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical enterprise that integrates drug research and development, production, and sales. It is located in Jinwan District, Zhuhai City, Guangdong Province and was established in 1999. On January 5, 2018, the company was listed on the Shenzhen Stock Exchange (stock abbreviation: Rundu Shares; stock code: 002923). The company's main business is the research and development, production and sales of chemical preparations, chemical APIs, and pharmaceutical intermediates. Its product applications cover many fields, including peptic ulcer, hypertension, surgical anesthesia, antipyretic and analgesic, anti infective, diabetes, and so on. The company has a comprehensive quality management system and has established a drug production and manufacturing center in strict accordance with national GMP requirements. The existing product production lines (including raw materials, tablets, capsules, intermediate preparations (pellets), etc.) have all passed the national new version of GMP certification. Some characteristic raw materials have passed official certifications such as the World Health Organization, the European Union, Japan, and some products have passed on-site inspections by the US FDA. The company is a national high-tech enterprise, a national enterprise technology center, a national green factory, a national postdoctoral research workstation, a national intellectual property advantage enterprise, a provincial-level enterprise technology center in Guangdong Province, a Guangdong Engineering Technology Research Center, and an innovative enterprise in Guangdong Province. It has strong technological innovation capabilities and a solid scientific research foundation. The company has always adhered to the development concept of "focusing on achieving excellence, and technology carrying the future". While continuing to maintain a leading position in the development of unique new drug formulations (such as microencapsulation technology and microencapsulation technology), enteric coated and sustained-release formulation technology, it actively develops the development of original new drugs and upgrades the technology of multiple types of drugs; Gradually promote the industrial upgrading strategy of vertical integration from raw materials to formulations; Carry out diversified research and development models, strengthen cooperation with domestic and foreign top technology research and development institutions, develop a series of high-end formulation products, promote the company's international trade, gradually achieve the company's internationalization strategy, and strive to become a leading enterprise in the production of characteristic products such as pellets, antihypertensive sartans, and anti peptic ulcer proton pump inhibitors in China. |
| Headquarter | Zhuhai |
| Establish Date | 12/30/1999 |
| Listed Code | 002923.SZ |
| Listed Date | 1/5/2018 |
| Chairman | Chen Xinmin. |
| CEO | Liu Jie. |
| Website | www.rdpharma.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
